Mobocertinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 55 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Mobocertinib - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Mobocertinib is an orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Mobocertinib is a Kinase Inhibitor. The mechanism of action of mobocertinib is as a HER1 Antagonist and Cytochrome P450 3A Inducer. Upon oral administration, mobocertinib,...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Mobocertinib is an orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Mobocertinib is a Kinase Inhibitor. The mechanism of action of mobocertinib is as a HER1 Antagonist and Cytochrome P450 3A Inducer. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly bind to and inhibit exon 20 insertion mutations of EGFR. This prevents EGFR-mediated...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Mobocertinib is an orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Mobocertinib is a Kinase Inhibitor. The mechanism of action of mobocertinib is as a HER1 Antagonist and Cytochrome P450 3A Inducer. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly bind to and inhibit exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2, and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization.

Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to “classical” EGFR mutants causing NSCLC) and is associated with resistance to standard targeted EGFR inhibitors. Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on EGFR exon 20 insertion mutant variants at concentrations 1.5- to 10-fold lower than those required to inhibit wild-type EGFR. Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic NSCLC in patients with EGFR exon 20 insertion mutations who have failed previous therapies.

Mobocertinib Succinate is the succinate salt form of mobocertinib, an orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly bind to and inhibit exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2, and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization.

Mechanism of Action

The epidermal growth factor receptor (EGFR) is a transmembrane receptor that regulates signaling pathways in the control of cellular proliferation. Mutations in these proteins have been associated with certain types of lung cancer, including non-small cell lung cancer (NSCLC). While the majority of _EGFR_ mutations associated with NSCLC involve the _EGFR_ L858R point mutation or exon 19 deletions (referred to as “classical” _EGFR_ mutations), less common _EGFR_ exon 20 insertion mutations carry a particularly poor prognosis and are associated with resistance to standard targeted EGFR inhibitors. Mobocertinib is an inhibitor of EGFR that irreversibly binds to and inhibits EGFR exon 20 insertion mutations at lower concentrations than wild-type EGFR proteins, exerting a pharmacologic effect on mutant variants at concentrations 1.5- to 10-fold lower than on wild-type proteins.

Mobocertinib is an inhibitor of EGFR that preferentially targets exon 20 insertion mutant variants. It is available as an oral capsule taken with or without food once daily. Mobocertinib can cause a concentration-dependent increase in QTc interval which may lead to life-threatening complications such as Torsades de Pointes. Patients with baseline risk factors for QTc prolongation should consider alternative medications or be monitored carefully throughout therapy. The use of concomitant QTc-prolonging medications should be avoided, as should concomitant inhibitors of CYP3A, as these may increase the concentration of mobocertinib and thus the risk of QTc-prolongation.

Indications

  • Mobocertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
  • For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (as detected by a US FDA-approved test) whose disease has progressed on or after platinum-based chemotherapy
  • Mobocertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.7
  • Locally Advanced Non-Small Cell Lung Cancer
  • Metastatic Non-Small Cell Lung Cancer

Use in Cancer

Mobocertinib succinate is approved to treat:

Mobocertinib succinate is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit to these patients.

Mobocertinib succinate is also being studied in the treatment of other conditions.

Contraindications

  • low amount of magnesium in the blood
  • low amount of calcium in the blood
  • low amount of potassium in the blood
  • torsades de pointes, a type of abnormal heart rhythm
  • prolonged QT interval on EKG
  • chronic heart failure
  • abnormal EKG with QT changes from birth
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • lung tissue problem

Dosage

Strengths: 40 mg

Non-Small Cell Lung Cancer

  • 160 mg orally once a day
  • Duration of therapy: Until disease progression or unacceptable toxicity

Renal Dose Adjustments

  • Mild to moderate renal dysfunction (estimated GFR 30 to 89 mL/min/1.73 m2): No adjustment recommended.
  • Severe renal dysfunction (estimated GFR less than 30 mL/min/1.73 m2): Data not available
  • Estimated GFR 30 to 89 mL/min/1.73 m2 by Modification of Diet in Renal Disease equation
  • The recommended dosage has not been established for patients with severe renal dysfunction.

Liver Dose Adjustments

  • Mild or moderate liver dysfunction: No adjustment is recommended.
  • Severe liver dysfunction: Data not available
  • Mild liver dysfunction: Total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin up to the upper limit of normal (ULN) and AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN (1 to 1.5 x ULN) and any AST
  • Moderate liver dysfunction: Total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin 1.5 to 3 x ULN and any AST
  • Severe liver dysfunction: Total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin greater than 3 x ULN and any AST
  • The recommended dosage has not been established for patients with severe liver dysfunction.

Dose Adjustments

Dose reduction levels for adverse reactions:

  • First dose reduction: 120 mg orally once a day
  • Second dose reduction: 80 mg orally once a day

QTc Interval Prolongation and Torsades de Pointes

  • Grade 2 (QTc interval 481 to 500 msec):
  • First occurrence: This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the same dose.
  • Recurrence: This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the next lower dose or should be permanently discontinued.
  • Grade 3 (QTc interval at least 501 msec or QTc interval increase of greater than 60 msec from baseline):
  • First occurrence: This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the next lower dose or should be permanently discontinued.
  • Recurrence: This drug should be permanently discontinued.
  • Grade 4 (torsades de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia): This drug should be permanently discontinued.

Interstitial Lung Disease (ILD)/Pneumonitis:

  • Any grade: This drug should be withheld if ILD/pneumonitis is suspected; if ILD/pneumonitis is confirmed, this drug should be permanently discontinued.

Decreased Ejection Fraction or Heart Failure:

  • Grade 2 decreased ejection fraction: This drug should be withheld until Grade 1 or lower or baseline.
  • If recovered to baseline within 2 weeks: This drug should resume at the same dose or the next lower dose.
  • If not recovered to baseline within 2 weeks: This drug should be permanently discontinued.
  • At least Grade 2 heart failure or Grade 3 or 4 decreased ejection fraction: This drug should be permanently discontinued.

Diarrhea:

  • Intolerable or recurrent Grade 2 or Grade 3: This drug should be withheld until Grade 1 or lower; this drug should resume at the same dose or the next lower dose.
  • Grade 4:
  • First occurrence: This drug should be withheld until Grade 1 or lower; this drug should resume at the next lower dose.
  • Recurrence: This drug should be permanently discontinued.

Other Adverse Reactions:

  • Intolerable or recurrent Grade 2 or Grade 3: This drug should be withheld until Grade 1 or lower; this drug should resume at the same dose or the next lower dose.
  • Grade 4:
  • First occurrence: This drug should be withheld until Grade 1 or lower.
  • If recovery occurs within 2 weeks: This drug should resume at the next lower dose.
  • If recovery does not occur within 2 weeks: This drug should be permanently discontinued.
  • Recurrence: This drug should be permanently discontinued.
  • Graded per National Cancer Institute Common Terminology Criteria for Adverse Events
  • Coadministration with Moderate CYP450 3A Inhibitors: Concomitant use should be avoided.
  • If coadministration cannot be avoided: The mobocertinib dose should be reduced by about 50% (i.e., from 160 to 80 mg, 120 to 40 mg, or 80 to 40 mg) and QTc interval should be monitored more frequently.
  • After the moderate CYP450 3A inhibitor has been discontinued for 3 to 5 elimination half-lives: Mobocertinib should resume at the dose taken before starting the moderate CYP450 3A inhibitor.

Administration advice:

  • Select patients with locally advanced/metastatic NSCLC for treatment with this drug based on the presence of EGFR exon 20 insertion mutations.
  • For information on US FDA-approved tests: fda.gov/CompanionDiagnostics
  • Administer with or without food, at the same time each day.
  • Swallow capsules whole; do not open, chew, or dissolve the contents of the capsules.
  • If a dose is vomited, do not administer an additional dose; administer the next dose as prescribed the following day.

Side Effects

The Most Common

  • nausea
  • vomiting
  • mouth sores
  • decreased appetite
  • weight loss
  • stomach pain
  • heartburn
  • rash
  • dry skin or itching
  • red, itchy, or irritated eyes
  • blurry vision
  • hair loss
  • nail infection
  • tiredness
  • muscle or bone pain
  • fatigue
  • runny nose
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • diarrhea
  • cough
  • fever
  • shortness of breath
  • chest pain
  • swelling of your ankles and feet

More common

  • Agitation
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • bloody eye
  • blurred vision or blue-green halos seen around objects
  • coma
  • confusion
  • decreased urine output
  • depression
  • diarrhea
  • dizziness
  • dry eyes
  • fainting
  • fast, pounding, or irregular heartbeat or pulse
  • headache
  • hostility
  • irregular heartbeat recurrent
  • irritability
  • lethargy
  • muscle twitching
  • nausea
  • nervousness
  • palpitations
  • pounding in the ears
  • rapid weight gain
  • redness, swelling, and/or itching of the eyelid
  • seizures
  • sensitivity of the eyes to light
  • stupor
  • swelling of the face, ankles, or hands
  • tingling of the hands or feet
  • unusual tiredness or weakness
  • unusual weight gain or loss

Rare

  • Chest pain or discomfort
  • chills
  • cough
  • dilated neck veins
  • fever
  • a general feeling of discomfort or illness
  • irregular breathing
  • swelling of the face, fingers feet, or lower legs
  • thickening of bronchial secretions
  • trouble breathing
  • Acid or sour stomach
  • belching
  • body aches or pain
  • burning, numbness, tingling, or painful sensations
  • cracked lips
  • decreased appetite
  • difficulty in moving
  • ear congestion
  • heartburn
  • indigestion
  • loosening of the fingernails
  • loss or thinning of the hair
  • loss of voice
  • muscle or bone pain
  • pain in the arms or legs
  • rash
  • redness or soreness around the fingernails
  • sneezing
  • sore throat
  • sores, ulcers, or white spots on the lips, tongue, or inside the mouth
  • stomach discomfort, upset, or pain
  • stuffy or runny nose
  • swelling or inflammation of the mouth
  • tender, swollen glands in the neck
  • trouble in swallowing
  • unsteadiness or awkwardness
  • voice changes
  • vomiting
  • weakness in the arms, hands, legs, or fee
  • Redness, swelling, pain of the skin
  • scaling of the skin on the hands and feet
  • ulceration of the skin

Drug interaction

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], EXKIVITY can cause fetal harm when administered to a pregnant woman. There are no available data on EXKIVITY use in pregnant women. Oral administration of mobocertinib to pregnant rats during the period of organogenesis resulted in embryolethality (embryo-fetal death) and maternal toxicity at plasma exposures approximately 1.7 times the human exposure based on AUC at the 160 mg once daily clinical dose (see Data). Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage
in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Lactation

There are no data on the presence of mobocertinib or its metabolites in human milk or their effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with EXKIVITY and for 1 week after the last dose.

How should this medicine be used?

Mobocertinib comes as a capsule to take by mouth. It is usually taken once daily with or without food. The length of your treatment depends on how well this medication works for you, and the side effects that you experience. Take mobocertinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take mobocertinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole; do not open, chew, crush, or dissolve them.

If you vomit after taking mobocertinib, do not take another dose. Continue your regular dosing schedule.

Your doctor may decrease your dose, or interrupt or discontinue your treatment. This depends on how well the medication works for you and the side effects you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take mobocertinib even if you feel well. Do not stop taking mobocertinib without talking to your doctor. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking mobocertinib,

  • tell your doctor and pharmacist if you are allergic to mobocertinib, any other medications, or any of the ingredients in mobocertinib capsules. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section and any of the following: angiotensin-converting enzyme (ACE) inhibitors such as benazepril (Lotensin, in Lotrel), captopril, enalapril (Epaned, Vasotec, in Vaseretic), fosinopril, lisinopril (Prinivil, Qbrelis, Zestril, in Zestoretic), moexipril, perindopril, (in Prestalia), quinapril (Accupril, in Accuretic, in Quinaretic), ramipril (Altace), and trandolapril; angiotensin receptor blockers (ARBs) such as azilsartan (Edarbi, in Edarbyclor), candesartan (Atacand, in Atacand HCT), eprosartan (Teveten), irbesartan (Avapro, in Avalide), losartan (Cozaar, in Hyzaar), and valsartan (Diovan, in Diovan HCT, in Exforge, others); diuretics (‘water pills’); efavirenz (Sustiva, in Atripla, in Symfi); hormonal contraceptives (birth control pills, patches, rings, implants, or injections); midazolam; rifampin (Rifadin, Rimactane); and sulfasalazine (Azulfidine). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with mobocertinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor if you have or have ever had asthma, emphysema, or other breathing problems (other than lung cancer); or kidney or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for 1 month after your final dose. Talk to your doctor about which methods you should use; hormonal contraceptives (birth control pills, patches, implants, rings, or injections) may not work well in women who are taking mobocertinib. If you are a male, you and your partner should use birth control during your treatment with mobocertinib and for 7 days after your final dose. If you or your partner become pregnant while taking mobocertinib, call your doctor immediately. Mobocertinib may harm the fetus.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are taking mobocertinib and for 7 days after the final dose.
  • you should know that mobocertinib often causes diarrhea, which can be severe. Call your doctor if you have diarrhea while taking mobocertinib. Your doctor may tell you to drink plenty of liquids, make changes in your diet, and take medication to control the diarrhea and prevent dehydration (loss of too much water from your body). Call your doctor immediately if you experience any of the following symptoms of dehydration: extreme thirst, dry mouth and/or skin, decreased urination, sunken eyes, or fast heartbeat.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Mobocertinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action The epidermal growth factor receptor (EGFR) is a transmembrane receptor that regulates signaling pathways in the control of cellular proliferation. Mutations in these proteins have been associated with certain types of lung cancer, including non-small cell lung cancer (NSCLC). While the majority of _EGFR_ mutations associated with NSCLC involve the _EGFR_ L858R point mutation or exon 19 deletions (referred to as "classical" _EGFR_ mutations), less common _EGFR_ exon 20 insertion mutations carry a particularly poor prognosis and are associated with resistance to standard targeted EGFR inhibitors. Mobocertinib is an inhibitor of EGFR that irreversibly binds to and inhibits EGFR exon 20 insertion mutations at lower concentrations than wild-type EGFR proteins, exerting a pharmacologic effect on mutant variants at concentrations 1.5- to 10-fold lower than on wild-type proteins. Mobocertinib is an inhibitor of EGFR that preferentially targets exon 20 insertion mutant variants. It is available as an oral capsule taken with or without food once daily. Mobocertinib can cause a concentration-dependent increase in QTc interval which may lead to life-threatening complications such as Torsades de Pointes. Patients with baseline risk factors for QTc prolongation should consider alternative medications or be monitored carefully throughout therapy. The use of concomitant QTc-prolonging medications should be avoided, as should concomitant inhibitors of CYP3A, as these may increase the concentration of mobocertinib and thus the risk of QTc-prolongation. Indications Mobocertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (as detected by a US FDA-approved test) whose disease has progressed on or after platinum-based chemotherapy Mobocertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.7 Locally Advanced Non-Small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer Use in Cancer Mobocertinib succinate is approved to treat: Non-small cell lung cancer (NSCLC) is locally advanced or metastatic and got worse during or after platinum chemotherapy. It is used in adults whose cancer has certain EGFR gene mutations. Mobocertinib succinate is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit to these patients. Mobocertinib succinate is also being studied in the treatment of other conditions. Contraindications low amount of magnesium in the blood low amount of calcium in the blood low amount of potassium in the blood torsades de pointes, a type of abnormal heart rhythm prolonged QT interval on EKG chronic heart failure abnormal EKG with QT changes from birth pregnancy a patient who is producing milk and breastfeeding lung tissue problem Dosage Strengths: 40 mg Non-Small Cell Lung Cancer 160 mg orally once a day Duration of therapy: Until disease progression or unacceptable toxicity Renal Dose Adjustments Mild to moderate renal dysfunction (estimated GFR 30 to 89 mL/min/1.73 m2): No adjustment recommended. Severe renal dysfunction (estimated GFR less than 30 mL/min/1.73 m2): Data not available Estimated GFR 30 to 89 mL/min/1.73 m2 by Modification of Diet in Renal Disease equation The recommended dosage has not been established for patients with severe renal dysfunction. Liver Dose Adjustments Mild or moderate liver dysfunction: No adjustment is recommended. Severe liver dysfunction: Data not available Mild liver dysfunction: Total bilirubin up to the upper limit of normal (ULN) and AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN (1 to 1.5 x ULN) and any AST Moderate liver dysfunction: Total bilirubin 1.5 to 3 x ULN and any AST Severe liver dysfunction: Total bilirubin greater than 3 x ULN and any AST The recommended dosage has not been established for patients with severe liver dysfunction. Dose Adjustments Dose reduction levels for adverse reactions: First dose reduction: 120 mg orally once a day Second dose reduction: 80 mg orally once a day QTc Interval Prolongation and Torsades de Pointes Grade 2 (QTc interval 481 to 500 msec): First occurrence: This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the same dose. Recurrence: This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the next lower dose or should be permanently discontinued. Grade 3 (QTc interval at least 501 msec or QTc interval increase of greater than 60 msec from baseline): First occurrence: This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the next lower dose or should be permanently discontinued. Recurrence: This drug should be permanently discontinued. Grade 4 (torsades de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia): This drug should be permanently discontinued. Interstitial Lung Disease (ILD)/Pneumonitis: Any grade: This drug should be withheld if ILD/pneumonitis is suspected; if ILD/pneumonitis is confirmed, this drug should be permanently discontinued. Decreased Ejection Fraction or Heart Failure: Grade 2 decreased ejection fraction: This drug should be withheld until Grade 1 or lower or baseline. If recovered to baseline within 2 weeks: This drug should resume at the same dose or the next lower dose. If not recovered to baseline within 2 weeks: This drug should be permanently discontinued. At least Grade 2 heart failure or Grade 3 or 4 decreased ejection fraction: This drug should be permanently discontinued. Diarrhea: Intolerable or recurrent Grade 2 or Grade 3: This drug should be withheld until Grade 1 or lower; this drug should resume at the same dose or the next lower dose. Grade 4: First occurrence: This drug should be withheld until Grade 1 or lower; this drug should resume at the next lower dose. Recurrence: This drug should be permanently discontinued. Other Adverse Reactions: Intolerable or recurrent Grade 2 or Grade 3: This drug should be withheld until Grade 1 or lower; this drug should resume at the same dose or the next lower dose. Grade 4: First occurrence: This drug should be withheld until Grade 1 or lower. If recovery occurs within 2 weeks: This drug should resume at the next lower dose. If recovery does not occur within 2 weeks: This drug should be permanently discontinued. Recurrence: This drug should be permanently discontinued. Graded per National Cancer Institute Common Terminology Criteria for Adverse Events Coadministration with Moderate CYP450 3A Inhibitors: Concomitant use should be avoided. If coadministration cannot be avoided: The mobocertinib dose should be reduced by about 50% (i.e., from 160 to 80 mg, 120 to 40 mg, or 80 to 40 mg) and QTc interval should be monitored more frequently. After the moderate CYP450 3A inhibitor has been discontinued for 3 to 5 elimination half-lives: Mobocertinib should resume at the dose taken before starting the moderate CYP450 3A inhibitor. Administration advice: Select patients with locally advanced/metastatic NSCLC for treatment with this drug based on the presence of EGFR exon 20 insertion mutations. For information on US FDA-approved tests: fda.gov/CompanionDiagnostics Administer with or without food, at the same time each day. Swallow capsules whole; do not open, chew, or dissolve the contents of the capsules. If a dose is vomited, do not administer an additional dose; administer the next dose as prescribed the following day. Side Effects The Most Common nausea vomiting mouth sores decreased appetite weight loss stomach pain heartburn rash dry skin or itching red, itchy, or irritated eyes blurry vision hair loss nail infection tiredness muscle or bone pain fatigue runny nose headache diarrhea cough fever shortness of breath chest pain swelling of your ankles and feet More common Agitation bloating or swelling of the face, arms, hands, lower legs, or feet bloody eye blurred vision or blue-green halos seen around objects coma confusion decreased urine output depression diarrhea dizziness dry eyes fainting fast, pounding, or irregular heartbeat or pulse headache hostility irregular heartbeat recurrent irritability lethargy muscle twitching nausea nervousness palpitations pounding in the ears rapid weight gain redness, swelling, and/or itching of the eyelid seizures sensitivity of the eyes to light stupor swelling of the face, ankles, or hands tingling of the hands or feet unusual tiredness or weakness unusual weight gain or loss Rare Chest pain or discomfort chills cough dilated neck veins fever a general feeling of discomfort or illness irregular breathing swelling of the face, fingers feet, or lower legs thickening of bronchial secretions trouble breathing Acid or sour stomach belching body aches or pain burning, numbness, tingling, or painful sensations cracked lips decreased appetite difficulty in moving ear congestion heartburn indigestion loosening of the fingernails loss or thinning of the hair loss of voice muscle or bone pain pain in the arms or legs rash redness or soreness around the fingernails sneezing sore throat sores, ulcers, or white spots on the lips, tongue, or inside the mouth stomach discomfort, upset, or pain stuffy or runny nose swelling or inflammation of the mouth tender, swollen glands in the neck trouble in swallowing unsteadiness or awkwardness voice changes vomiting weakness in the arms, hands, legs, or fee Redness, swelling, pain of the skin scaling of the skin on the hands and feet ulceration of the skin Drug interaction DRUG INTERACTION Abametapir The serum concentration of Mobocertinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Mobocertinib can be increased when combined with Abatacept. Abemaciclib The serum concentration of Abemaciclib can be decreased when it is combined with Mobocertinib. Acalabrutinib The serum concentration of Acalabrutinib can be decreased when it is combined with Mobocertinib. Acebutolol The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Mobocertinib. Acenocoumarol The serum concentration of Acenocoumarol can be decreased when it is combined with Mobocertinib. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Mobocertinib. Adalimumab The metabolism of Mobocertinib can be increased when combined with Adalimumab. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Mobocertinib. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Mobocertinib. Alectinib The serum concentration of Alectinib can be decreased when it is combined with Mobocertinib. Alfentanil The metabolism of Mobocertinib can be decreased when combined with Alfentanil. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Mobocertinib. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Mobocertinib. Alpelisib The serum concentration of Alpelisib can be decreased when it is combined with Mobocertinib. Alprazolam The metabolism of Mobocertinib can be decreased when combined with Alprazolam. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Mobocertinib. Ambrisentan The metabolism of Mobocertinib can be decreased when combined with Ambrisentan. Amifampridine The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Mobocertinib. Aminophylline The serum concentration of Aminophylline can be decreased when it is combined with Mobocertinib. Amiodarone The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Mobocertinib. Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Mobocertinib. Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Mobocertinib. Amlodipine The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Mobocertinib. Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Mobocertinib. Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Mobocertinib. Amprenavir The serum concentration of Mobocertinib can be increased when it is combined with Amprenavir. Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Mobocertinib. Anakinra The metabolism of Mobocertinib can be increased when combined with Anakinra. Antazoline The risk or severity of QTc prolongation can be increased when Antazoline is combined with Mobocertinib. Apalutamide The serum concentration of Mobocertinib can be decreased when it is combined with Apalutamide. Apixaban The metabolism of Mobocertinib can be decreased when combined with Apixaban. Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Mobocertinib. Apremilast The metabolism of Mobocertinib can be increased when combined with Apremilast. Aprepitant The metabolism of Mobocertinib can be decreased when combined with Aprepitant. Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Mobocertinib. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Mobocertinib. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Mobocertinib. Armodafinil The metabolism of Mobocertinib can be increased when combined with Armodafinil. Arsenic trioxide The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Mobocertinib. Artemether The risk or severity of QTc prolongation can be increased when Artemether is combined with Mobocertinib. Asenapine The risk or severity of QTc prolongation can be increased when Asenapine is combined with Mobocertinib. Astemizole The risk or severity of QTc prolongation can be increased when Astemizole is combined with Mobocertinib. Asunaprevir The metabolism of Mobocertinib can be decreased when combined with Asunaprevir. Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Mobocertinib. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Mobocertinib. Atorvastatin The metabolism of Mobocertinib can be decreased when combined with Atorvastatin. Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Mobocertinib. Avanafil The serum concentration of Avanafil can be increased when it is combined with Mobocertinib. Axitinib The serum concentration of Axitinib can be decreased when it is combined with Mobocertinib. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Mobocertinib. Azelastine The metabolism of Mobocertinib can be decreased when combined with Azelastine. Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Mobocertinib. Beclomethasone The metabolism of Mobocertinib can be increased when combined with Beclomethasone dipropionate. Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Mobocertinib. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Mobocertinib. Bepridil The risk or severity of QTc prolongation can be increased when Bepridil is combined with Mobocertinib. Berotralstat The metabolism of Mobocertinib can be decreased when combined with Berotralstat. Betamethasone The metabolism of Mobocertinib can be increased when combined with Betamethasone. Betamethasone The metabolism of Mobocertinib can be increased when combined with Betamethasone phosphate. Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Mobocertinib. Bicalutamide The serum concentration of Bicalutamide can be decreased when it is combined with Mobocertinib. Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Mobocertinib. Bimekizumab The metabolism of Mobocertinib can be increased when combined with Bimekizumab. Boceprevir The serum concentration of Mobocertinib can be increased when it is combined with Boceprevir. Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Mobocertinib. Bosutinib The serum concentration of Bosutinib can be decreased when it is combined with Mobocertinib. Brentuximab The serum concentration of Brentuximab vedotin can be decreased when it is combined with Mobocertinib. Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Mobocertinib. Brigatinib The serum concentration of Brigatinib can be decreased when it is combined with Mobocertinib. Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Mobocertinib. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Mobocertinib. Budesonide The metabolism of Mobocertinib can be increased when combined with Budesonide. Buprenorphine The metabolism of Mobocertinib can be decreased when combined with Buprenorphine. Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Mobocertinib. Buspirone The metabolism of Mobocertinib can be decreased when combined with Buspirone. Busulfan The serum concentration of Busulfan can be decreased when it is combined with Mobocertinib. Butriptyline The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Mobocertinib. Cabazitaxel The serum concentration of Cabazitaxel can be decreased when it is combined with Mobocertinib. Cabergoline The serum concentration of Cabergoline can be decreased when it is combined with Mobocertinib. Canakinumab The metabolism of Mobocertinib can be increased when combined with Canakinumab. Cannabidiol The metabolism of Mobocertinib can be decreased when combined with Cannabidiol. Carbamazepine The serum concentration of Mobocertinib can be decreased when it is combined with Carbamazepine. Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Mobocertinib. Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Mobocertinib. Cenobamate The serum concentration of Mobocertinib can be decreased when it is combined with Cenobamate. Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Mobocertinib. Cerivastatin The metabolism of Mobocertinib can be decreased when combined with Cerivastatin. Certolizumab pegol The metabolism of Mobocertinib can be increased when combined with Certolizumab pegol. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Mobocertinib. Chloramphenicol The metabolism of Mobocertinib can be decreased when combined with Chloramphenicol. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Mobocertinib. Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Mobocertinib. Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Mobocertinib. Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Mobocertinib. Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Mobocertinib. Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Mobocertinib. Cimetidine The metabolism of Mobocertinib can be decreased when combined with Cimetidine. Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Mobocertinib. Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Mobocertinib. Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mobocertinib. Cisapride The risk or severity of QTc prolongation can be increased when Cisapride is combined with Mobocertinib. Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Mobocertinib. Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Mobocertinib. Clemastine The risk or severity of QTc prolongation can be increased when Clemastine is combined with Mobocertinib. Clindamycin The metabolism of Mobocertinib can be decreased when combined with Clindamycin. Clobetasol The metabolism of Mobocertinib can be increased when combined with Clobetasol propionate. Clofazimine The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Mobocertinib. Clomipramine The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Mobocertinib. Clonidine The serum concentration of Clonidine can be decreased when it is combined with Mobocertinib. Clopidogrel The metabolism of Mobocertinib can be decreased when combined with Clopidogrel. Clozapine The risk or severity of QTc prolongation can be increased when Clozapine is combined with Mobocertinib. Cobicistat The serum concentration of Mobocertinib can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be decreased when it is combined with Mobocertinib. Cocaine The risk or severity of QTc prolongation can be increased when Cocaine is combined with Mobocertinib. Conivaptan The serum concentration of Mobocertinib can be increased when it is combined with Conivaptan. Copanlisib The serum concentration of Copanlisib can be decreased when it is combined with Mobocertinib. Cortisone acetate The metabolism of Mobocertinib can be increased when combined with Cortisone acetate. Crizotinib The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Mobocertinib. Curcumin The serum concentration of Mobocertinib can be increased when it is combined with Curcumin. Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Mobocertinib. Cyclophosphamide The serum concentration of Cyclophosphamide can be decreased when it is combined with Mobocertinib. Cyclosporine The serum concentration of Cyclosporine can be decreased when it is combined with Mobocertinib. Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Mobocertinib. Cyproterone acetate The serum concentration of Cyproterone acetate can be decreased when it is combined with Mobocertinib. Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Mobocertinib. Daclatasvir The metabolism of Mobocertinib can be decreased when combined with Daclatasvir. Dacomitinib The serum concentration of Dacomitinib can be decreased when it is combined with Mobocertinib. Danazol The serum concentration of Mobocertinib can be increased when it is combined with Danazol. Dapsone The metabolism of Mobocertinib can be decreased when combined with Dapsone. Darunavir The serum concentration of Mobocertinib can be increased when it is combined with Darunavir. Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Mobocertinib. Daunorubicin The metabolism of Mobocertinib can be increased when combined with Daunorubicin. Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mobocertinib. Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Mobocertinib. Delamanid The risk or severity of QTc prolongation can be increased when Delamanid is combined with Mobocertinib. Delavirdine The serum concentration of Mobocertinib can be increased when it is combined with Delavirdine. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Mobocertinib. Desipramine The risk or severity of QTc prolongation can be increased when Desipramine is combined with Mobocertinib. Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Mobocertinib. Desogestrel The serum concentration of Desogestrel can be decreased when it is combined with Mobocertinib. Desvenlafaxine The metabolism of Mobocertinib can be decreased when combined with Desvenlafaxine. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Deutetrabenazine is combined with Mobocertinib. Dexamethasone The serum concentration of Mobocertinib can be decreased when it is combined with Dexamethasone. Dexamethasone The metabolism of Mobocertinib can be increased when combined with Dexamethasone acetate. Dexbrompheniram The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Mobocertinib. Dexchlorphenira The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Mobocertinib. Dextromethorphan The metabolism of Mobocertinib can be decreased when combined with Dextromethorphan. Diazepam The metabolism of Mobocertinib can be decreased when combined with Diazepam. Dienogest The serum concentration of Dienogest can be decreased when it is combined with Mobocertinib. Diethylstilbestrol The serum concentration of Diethylstilbestrol can be decreased when it is combined with Mobocertinib. Difluocortolone The metabolism of Mobocertinib can be increased when combined with Difluocortolone. Digitoxin The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Mobocertinib. Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Mobocertinib. Dihydroergotamine The serum concentration of Dihydroergotamine can be decreased when it is combined with Mobocertinib. Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Mobocertinib. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Mobocertinib. Diphenhydramine The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Mobocertinib. Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Mobocertinib. Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Mobocertinib. Docetaxel The serum concentration of Docetaxel can be decreased when it is combined with Mobocertinib. Dofetilide The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Mobocertinib. Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Mobocertinib. Domperidone The risk or severity of QTc prolongation can be increased when Domperidone is combined with Mobocertinib. Doravirine The metabolism of Mobocertinib can be decreased when combined with Doravirine. Dosulepin The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Mobocertinib. Doxepin The risk or severity of QTc prolongation can be increased when Doxepin is combined with Mobocertinib. Doxorubicin The serum concentration of Doxorubicin can be decreased when it is combined with Mobocertinib. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Mobocertinib. Dronedarone The risk or severity of QTc prolongation can be increased when Dronedarone is combined with Mobocertinib. Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Mobocertinib. Drospirenone The serum concentration of Drospirenone can be decreased when it is combined with Mobocertinib. Dutasteride The metabolism of Mobocertinib can be decreased when combined with Dutasteride. Ebastine The risk or severity of QTc prolongation can be increased when Ebastine is combined with Mobocertinib. Econazole The serum concentration of Mobocertinib can be increased when it is combined with Econazole. Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Mobocertinib. Elbasvir The metabolism of Mobocertinib can be decreased when combined with Elbasvir. Elexacaftor The metabolism of Mobocertinib can be decreased when combined with Elexacaftor. Eliglustat The risk or severity of QTc prolongation can be increased when Eliglustat is combined with Mobocertinib. Elvitegravir The serum concentration of Mobocertinib can be increased when it is combined with Elvitegravir. Emapalumab The metabolism of Mobocertinib can be increased when combined with Emapalumab. Emedastine The risk or severity of QTc prolongation can be increased when Emedastine is combined with Mobocertinib. Enasidenib The serum concentration of Enasidenib can be decreased when it is combined with Mobocertinib. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Mobocertinib. Encorafenib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Mobocertinib. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Mobocertinib. Entrectinib The risk or severity of QTc prolongation can be increased when Entrectinib is combined with Mobocertinib. Enzalutamide The serum concentration of Mobocertinib can be decreased when it is combined with Enzalutamide. Epinastine The risk or severity of QTc prolongation can be increased when Epinastine is combined with Mobocertinib. Eplerenone The metabolism of Mobocertinib can be decreased when combined with Eplerenone. Erdafitinib The serum concentration of Erdafitinib can be decreased when it is combined with Mobocertinib. Ergotamine The serum concentration of Mobocertinib can be increased when it is combined with Ergotamine. Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Mobocertinib. Erlotinib The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Mobocertinib. Erythromycin The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Mobocertinib. Escitalopram The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Mobocertinib. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Mobocertinib. Estradiol The serum concentration of Estradiol can be decreased when it is combined with Mobocertinib. Estradiol acetate The metabolism of Mobocertinib can be decreased when combined with Estradiol acetate. Estradiol benzoate The serum concentration of Estradiol benzoate can be decreased when it is combined with Mobocertinib. Estradiol cypionate The serum concentration of Estradiol cypionate can be decreased when it is combined with Mobocertinib. Estradiol dienanthate The metabolism of Mobocertinib can be decreased when combined with Estradiol dienanthate. Estradiol valerate The serum concentration of Estradiol valerate can be decreased when it is combined with Mobocertinib. Estrone sulfate The serum concentration of Estrone sulfate can be decreased when it is combined with Mobocertinib. Etanercept The metabolism of Mobocertinib can be increased when combined with Etanercept. Ethinylestradiol The serum concentration of Ethinylestradiol can be decreased when it is combined with Mobocertinib. Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Mobocertinib. Ethynodiol The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Mobocertinib. Etonogestrel The serum concentration of Etonogestrel can be decreased when it is combined with Mobocertinib. Etoposide The serum concentration of Etoposide can be decreased when it is combined with Mobocertinib. Everolimus The serum concentration of Everolimus can be decreased when it is combined with Mobocertinib. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Mobocertinib. Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mobocertinib. Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Mobocertinib. Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Mobocertinib. Fentanyl The metabolism of Mobocertinib can be decreased when combined with Fentanyl. Fexinidazole The risk or severity of adverse effects can be increased when Mobocertinib is combined with Fexinidazole. Finasteride The metabolism of Mobocertinib can be decreased when combined with Finasteride. Flecainide The risk or severity of QTc prolongation can be increased when Flecainide is combined with Mobocertinib. Fluconazole The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Mobocertinib. Fluocinonide The metabolism of Mobocertinib can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Mobocertinib can be increased when combined with Fluocortolone. Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Mobocertinib. Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Mobocertinib. Flupentixol The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Mobocertinib. Fluspirilene The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Mobocertinib. Flutamide The metabolism of Mobocertinib can be decreased when combined with Flutamide. Fluticasone The metabolism of Mobocertinib can be decreased when combined with Fluticasone. Fluticasone furoate The metabolism of Mobocertinib can be decreased when combined with Fluticasone furoate. Fluticasone The metabolism of Mobocertinib can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Mobocertinib can be decreased when combined with Fluvastatin. Fluvoxamine The metabolism of Mobocertinib can be decreased when combined with Fluvoxamine. Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Mobocertinib. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Mobocertinib. Fosnetupitant The metabolism of Mobocertinib can be decreased when combined with Fosnetupitant. Fosphenytoin The serum concentration of Mobocertinib can be decreased when it is combined with Fosphenytoin. Fusidic acid The metabolism of Mobocertinib can be decreased when combined with Fusidic acid. Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Mobocertinib. Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Mobocertinib. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Mobocertinib. Gefitinib The metabolism of Mobocertinib can be decreased when combined with Gefitinib. Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Mobocertinib. Gestrinone The serum concentration of Gestrinone can be decreased when it is combined with Mobocertinib. Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Mobocertinib. Glasdegib The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Mobocertinib. Glyburide The metabolism of Mobocertinib can be decreased when combined with Glyburide. Golimumab The metabolism of Mobocertinib can be increased when combined with Golimumab. Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mobocertinib. Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Mobocertinib. Grepafloxacin The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Mobocertinib. Halofantrine The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Mobocertinib. Haloperidol The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Mobocertinib. Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Mobocertinib. Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Mobocertinib. Hydrocortisone The metabolism of Mobocertinib can be decreased when combined with Hydrocortisone. Hydrocortisone The metabolism of Mobocertinib can be decreased when combined with Hydrocortisone acetate. Hydrocortisone The metabolism of Mobocertinib can be decreased when combined with Hydrocortisone butyrate. Hydrocortisone The metabolism of Mobocertinib can be decreased when combined with Hydrocortisone cypionate. Hydrocortisone The metabolism of Mobocertinib can be decreased when combined with Hydrocortisone phosphate. Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Mobocertinib. Hydroxyprogester The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Mobocertinib. Hydroxyzine The risk or severity of QTc prolongation can be increased when Mobocertinib is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Mobocertinib. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mobocertinib. Ibrutinib The metabolism of Mobocertinib can be decreased when combined with Ibrutinib. Ibutilide The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Mobocertinib. Idelalisib The serum concentration of Idelalisib can be decreased when it is combined with Mobocertinib. Ifosfamide The serum concentration of Ifosfamide can be decreased when it is combined with Mobocertinib. Iloperidone The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Mobocertinib. Imatinib The risk or severity of QTc prolongation can be increased when Imatinib is combined with Mobocertinib. Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Mobocertinib. Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Mobocertinib. Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Mobocertinib. Indinavir The serum concentration of Mobocertinib can be increased when it is combined with Indinavir. Infliximab The metabolism of Mobocertinib can be increased when combined with Infliximab. Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Mobocertinib. Irinotecan The serum concentration of Irinotecan can be decreased when it is combined with Mobocertinib. Isavuconazole The metabolism of Mobocertinib can be decreased when combined with Isavuconazole. Isavuconazonium The metabolism of Mobocertinib can be decreased when combined with Isavuconazonium. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Mobocertinib. Isoniazid The metabolism of Mobocertinib can be decreased when combined with Isoniazid. Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Mobocertinib. Istradefylline The metabolism of Mobocertinib can be decreased when combined with Istradefylline. Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Mobocertinib. Ivabradine The risk or severity of QTc prolongation can be increased when Ivabradine is combined with Mobocertinib. Ivacaftor The metabolism of Mobocertinib can be decreased when combined with Ivacaftor. Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Mobocertinib. Ixabepilone The serum concentration of Ixabepilone can be decreased when it is combined with Mobocertinib. Ixazomib The serum concentration of Ixazomib can be decreased when it is combined with Mobocertinib. Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Mobocertinib. Lacidipine The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Mobocertinib. Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Mobocertinib. Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Mobocertinib. Lefamulin The risk or severity of QTc prolongation can be increased when Lefamulin is combined with Mobocertinib. Lemborexant The metabolism of Mobocertinib can be decreased when combined with Lemborexant. Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Mobocertinib. Lercanidipine The metabolism of Mobocertinib can be decreased when combined with Lercanidipine. Letermovir The metabolism of Mobocertinib can be decreased when combined with Letermovir. Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mobocertinib. Levacetylmethadol The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Mobocertinib. Levamlodipine The metabolism of Mobocertinib can be decreased when combined with Levamlodipine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Mobocertinib. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Mobocertinib. Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mobocertinib. Levoketoconazole The risk or severity of QTc prolongation can be increased when Levoketoconazole is combined with Mobocertinib. Levonorgestrel The serum concentration of Levonorgestrel can be decreased when it is combined with Mobocertinib. Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Mobocertinib. Lidocaine The metabolism of Mobocertinib can be decreased when combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Mobocertinib. Linagliptin The metabolism of Mobocertinib can be decreased when combined with Linagliptin. Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Mobocertinib. Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Mobocertinib. Lomitapide The serum concentration of Lomitapide can be decreased when it is combined with Mobocertinib. Lonafarnib The serum concentration of Mobocertinib can be increased when it is combined with Lonafarnib. Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Mobocertinib. Lopinavir The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Mobocertinib. Lorlatinib The metabolism of Mobocertinib can be decreased when combined with Lorlatinib. Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Mobocertinib. Lovastatin The metabolism of Mobocertinib can be decreased when combined with Lovastatin. Lumacaftor The serum concentration of Mobocertinib can be decreased when it is combined with Lumacaftor. Lumefantrine The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Mobocertinib. Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Mobocertinib. Lynestrenol The serum concentration of Lynestrenol can be decreased when it is combined with Mobocertinib. Macimorelin The risk or severity of QTc prolongation can be increased when Macimorelin is combined with Mobocertinib. Malathion The risk or severity of QTc prolongation can be increased when Malathion is combined with Mobocertinib. Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Mobocertinib. Mavacamten The serum concentration of Mobocertinib can be decreased when it is combined with Mavacamten. Medroxyprogeste The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mobocertinib. Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Mobocertinib. Megestrol acetate The serum concentration of Megestrol acetate can be decreased when it is combined with Mobocertinib. Meprednisone The metabolism of Mobocertinib can be increased when combined with Meprednisone. Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Mobocertinib. Mesoridazine The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Mobocertinib. Mestranol The serum concentration of Mestranol can be decreased when it is combined with Mobocertinib. Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Mobocertinib. Methimazole The serum concentration of Mobocertinib can be increased when it is combined with Methimazole. Methotrexate The serum concentration of Methotrexate can be decreased when it is combined with Mobocertinib. Methotrimeprazine The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Mobocertinib. Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Mobocertinib. Methylene blue The metabolism of Mobocertinib can be decreased when combined with Methylene blue. Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Mobocertinib. Metreleptin The metabolism of Mobocertinib can be increased when combined with Metreleptin. Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Mobocertinib. Miconazole The metabolism of Mobocertinib can be decreased when combined with Miconazole. Midazolam The metabolism of Mobocertinib can be decreased when combined with Midazolam. Midostaurin The serum concentration of Mobocertinib can be decreased when it is combined with Midostaurin. Mifepristone The risk or severity of QTc prolongation can be increased when Mifepristone is combined with Mobocertinib. Milnacipran The metabolism of Mobocertinib can be decreased when combined with Milnacipran. Mirabegron The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Mobocertinib. Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Mobocertinib. Mitotane The serum concentration of Mobocertinib can be decreased when it is combined with Mitotane. Mizolastine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Mobocertinib. Modafinil The metabolism of Mobocertinib can be increased when combined with Modafinil. Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Mobocertinib. Mometasone The metabolism of Mobocertinib can be increased when combined with Mometasone furoate. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Mobocertinib. Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mobocertinib. Mycophenolate The metabolism of Mobocertinib can be decreased when combined with Mycophenolate mofetil. Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Mobocertinib. Naloxone The serum concentration of Mobocertinib can be increased when it is combined with Naloxone. Nateglinide The metabolism of Mobocertinib can be decreased when combined with Nateglinide. Nefazodone The serum concentration of Mobocertinib can be increased when it is combined with Nefazodone. Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Mobocertinib. Neratinib The serum concentration of Neratinib can be decreased when it is combined with Mobocertinib. Netupitant The metabolism of Mobocertinib can be decreased when combined with Netupitant. Nevirapine The metabolism of Mobocertinib can be decreased when combined with Nevirapine. Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Mobocertinib. Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Mobocertinib. Nilotinib The risk or severity of QTc prolongation can be increased when Nilotinib is combined with Mobocertinib. Nilvadipine The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Mobocertinib. Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Mobocertinib. Nisoldipine The metabolism of Mobocertinib can be decreased when combined with Nisoldipine. Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Mobocertinib. Nomegestrol The serum concentration of Nomegestrol can be decreased when it is combined with Mobocertinib. Nomegestrol The serum concentration of Nomegestrol acetate can be decreased when it is combined with Mobocertinib. Nonoxynol-9 The serum concentration of Nonoxynol-9 can be decreased when it is combined with Mobocertinib. Norelgestromin The serum concentration of Norelgestromin can be decreased when it is combined with Mobocertinib. Norethisterone The serum concentration of Norethisterone can be decreased when it is combined with Mobocertinib. Norethynodrel The serum concentration of Norethynodrel can be decreased when it is combined with Mobocertinib. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Mobocertinib. Norgestimate The serum concentration of Norgestimate can be decreased when it is combined with Mobocertinib. Norgestrel The serum concentration of Norgestrel can be decreased when it is combined with Mobocertinib. Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Mobocertinib. Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mobocertinib. Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Mobocertinib. Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Mobocertinib. Olaparib The serum concentration of Olaparib can be decreased when it is combined with Mobocertinib. Olodaterol The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Mobocertinib. Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Mobocertinib. Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Mobocertinib. Osilodrostat The metabolism of Mobocertinib can be decreased when combined with Osilodrostat. Osimertinib The serum concentration of Osimertinib can be decreased when it is combined with Mobocertinib. Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mobocertinib. Oxatomide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Mobocertinib. Oxcarbazepine The metabolism of Mobocertinib can be increased when combined with Oxcarbazepine. Oxprenolol The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Mobocertinib. Oxybutynin The metabolism of Mobocertinib can be decreased when combined with Oxybutynin. Oxycodone The metabolism of Mobocertinib can be decreased when combined with Oxycodone. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mobocertinib. Paclitaxel The serum concentration of Paclitaxel can be decreased when it is combined with Mobocertinib. Pacritinib The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Mobocertinib. Palbociclib The serum concentration of Palbociclib can be decreased when it is combined with Mobocertinib. Paliperidone The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Mobocertinib. Panobinostat The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Mobocertinib. Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mobocertinib. Paritaprevir The metabolism of Mobocertinib can be decreased when combined with Paritaprevir. Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Mobocertinib. Pazopanib The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Mobocertinib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Mobocertinib. Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Mobocertinib. Pentobarbital The serum concentration of Mobocertinib can be decreased when it is combined with Pentobarbital. Perampanel The metabolism of Mobocertinib can be decreased when combined with Perampanel. Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Mobocertinib. Perhexiline The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Mobocertinib. Pexidartinib The serum concentration of Pexidartinib can be decreased when it is combined with Mobocertinib. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Mobocertinib. Phenobarbital The serum concentration of Mobocertinib can be decreased when it is combined with Phenobarbital. Phenprocoumon The serum concentration of Phenprocoumon can be decreased when it is combined with Mobocertinib. Phenytoin The serum concentration of Mobocertinib can be decreased when it is combined with Phenytoin. Pimozide The risk or severity of QTc prolongation can be increased when Pimozide is combined with Mobocertinib. Pinaverium The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Mobocertinib. Pitolisant The risk or severity of QTc prolongation can be increased when Pitolisant is combined with Mobocertinib. Pomalidomide The serum concentration of Pomalidomide can be decreased when it is combined with Mobocertinib. Ponatinib The serum concentration of Ponatinib can be decreased when it is combined with Mobocertinib. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Mobocertinib. Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Mobocertinib. Pralsetinib The metabolism of Mobocertinib can be decreased when combined with Pralsetinib. Praziquantel The metabolism of Mobocertinib can be decreased when combined with Praziquantel. Prednisolone The metabolism of Mobocertinib can be increased when combined with Prednisolone phosphate. Prednisone The metabolism of Mobocertinib can be increased when combined with Prednisone acetate. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Mobocertinib. Prenylamine The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Mobocertinib. Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Mobocertinib. Primidone The serum concentration of Mobocertinib can be decreased when it is combined with Primidone. Probucol The risk or severity of QTc prolongation can be increased when Probucol is combined with Mobocertinib. Procainamide The risk or severity of QTc prolongation can be increased when Procainamide is combined with Mobocertinib. Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Mobocertinib. Progesterone The serum concentration of Progesterone can be decreased when it is combined with Mobocertinib. Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Mobocertinib. Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Mobocertinib. Propafenone The risk or severity of QTc prolongation can be increased when Propafenone is combined with Mobocertinib. Propofol The risk or severity of QTc prolongation can be increased when Propofol is combined with Mobocertinib. Propranolol The risk or severity of QTc prolongation can be increased when Propranolol is combined with Mobocertinib. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Mobocertinib. Quetiapine The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Mobocertinib. Quinidine The risk or severity of QTc prolongation can be increased when Quinidine is combined with Mobocertinib. Quinine The risk or severity of QTc prolongation can be increased when Quinine is combined with Mobocertinib. Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Mobocertinib. Regorafenib The serum concentration of Regorafenib can be decreased when it is combined with Mobocertinib. Relugolix The metabolism of Mobocertinib can be decreased when combined with Relugolix. Reserpine The metabolism of Mobocertinib can be increased when combined with Reserpine. Ribociclib The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Mobocertinib. Rifampicin The serum concentration of Mobocertinib can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Mobocertinib can be decreased when it is combined with Rifamycin. Rifapentine The serum concentration of Mobocertinib can be decreased when it is combined with Rifapentine. Rilonacept The metabolism of Mobocertinib can be increased when combined with Rilonacept. Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Mobocertinib. Rimexolone The serum concentration of Mobocertinib can be decreased when it is combined with Rimexolone. Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Mobocertinib. Ritonavir The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Mobocertinib. Rivaroxaban The metabolism of Mobocertinib can be decreased when combined with Rivaroxaban. Romidepsin The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Mobocertinib. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Mobocertinib. Rosuvastatin The metabolism of Mobocertinib can be decreased when combined with Rosuvastatin. Roxithromycin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Mobocertinib. Rucaparib The metabolism of Mobocertinib can be decreased when combined with Rucaparib. Rupatadine The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Mobocertinib. Ruxolitinib The serum concentration of Ruxolitinib can be decreased when it is combined with Mobocertinib. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mobocertinib. Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mobocertinib. Saquinavir The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Mobocertinib. Satralizumab The serum concentration of Mobocertinib can be decreased when it is combined with Satralizumab. Saxagliptin The metabolism of Mobocertinib can be decreased when combined with Saxagliptin. Secukinumab The metabolism of Mobocertinib can be increased when combined with Secukinumab. Segesterone The serum concentration of Segesterone acetate can be decreased when it is combined with Mobocertinib. Selpercatinib The risk or severity of QTc prolongation can be increased when Selpercatinib is combined with Mobocertinib. Selumetinib The metabolism of Mobocertinib can be decreased when combined with Selumetinib. Sertindole The risk or severity of QTc prolongation can be increased when Sertindole is combined with Mobocertinib. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Mobocertinib. Sildenafil The metabolism of Mobocertinib can be decreased when combined with Sildenafil. Siltuximab The metabolism of Mobocertinib can be increased when combined with Siltuximab. Simeprevir The metabolism of Mobocertinib can be decreased when combined with Simeprevir. Simvastatin The metabolism of Mobocertinib can be decreased when combined with Simvastatin. Siponimod The serum concentration of Siponimod can be decreased when it is combined with Mobocertinib. Sirolimus The serum concentration of Sirolimus can be decreased when it is combined with Mobocertinib. Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Mobocertinib. Somatrogon The metabolism of Mobocertinib can be increased when combined with Somatrogon. Sonidegib The serum concentration of Sonidegib can be decreased when it is combined with Mobocertinib. Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Mobocertinib. Sotalol The risk or severity of QTc prolongation can be increased when Sotalol is combined with Mobocertinib. Sotorasib The serum concentration of Mobocertinib can be decreased when it is combined with Sotorasib. Sparfloxacin The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Mobocertinib. St. John's Wort The serum concentration of Mobocertinib can be decreased when it is combined with St. John's Wort. Stiripentol The serum concentration of Mobocertinib can be increased when it is combined with Stiripentol. Sulfamethoxazole The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Mobocertinib. Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Mobocertinib. Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Mobocertinib. Sultopride The risk or severity of QTc prolongation can be increased when Sultopride is combined with Mobocertinib. Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Mobocertinib. Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Mobocertinib. Tadalafil The metabolism of Mobocertinib can be decreased when combined with Tadalafil. Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Mobocertinib. Tegafur The serum concentration of Tegafur can be decreased when it is combined with Mobocertinib. Telaprevir The serum concentration of Mobocertinib can be increased when it is combined with Telaprevir. Telavancin The risk or severity of QTc prolongation can be increased when Telavancin is combined with Mobocertinib. Telithromycin The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Mobocertinib. Telotristat ethyl The serum concentration of Mobocertinib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The serum concentration of Temsirolimus can be decreased when it is combined with Mobocertinib. Teniposide The serum concentration of Teniposide can be decreased when it is combined with Mobocertinib. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Mobocertinib. Terfenadine The risk or severity of QTc prolongation can be increased when Terfenadine is combined with Mobocertinib. Terlipressin The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Mobocertinib. Testosterone The metabolism of Mobocertinib can be decreased when combined with Testosterone. Testosterone The metabolism of Mobocertinib can be decreased when combined with Testosterone cypionate. Testosterone The serum concentration of Testosterone enanthate can be decreased when it is combined with Mobocertinib. Tetrabenazine The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Mobocertinib. Tezacaftor The metabolism of Mobocertinib can be decreased when combined with Tezacaftor. Thalidomide The metabolism of Mobocertinib can be increased when combined with Thalidomide. Theophylline The serum concentration of Theophylline can be decreased when it is combined with Mobocertinib. Thioridazine The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Mobocertinib. Thiotepa The serum concentration of Thiotepa can be decreased when it is combined with Mobocertinib. Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Mobocertinib. Ticagrelor The metabolism of Mobocertinib can be decreased when combined with Ticagrelor. Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Mobocertinib. Tipranavir The serum concentration of Mobocertinib can be increased when it is combined with Tipranavir. Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Mobocertinib. Tocilizumab The metabolism of Mobocertinib can be increased when combined with Tocilizumab. Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Mobocertinib. Tolvaptan The serum concentration of Tolvaptan can be decreased when it is combined with Mobocertinib. Toremifene The risk or severity of QTc prolongation can be increased when Toremifene is combined with Mobocertinib. Trabectedin The serum concentration of Trabectedin can be decreased when it is combined with Mobocertinib. Trastuzumab The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Mobocertinib. Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mobocertinib. Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Mobocertinib. Tretinoin The metabolism of Mobocertinib can be decreased when combined with Tretinoin. Triamcinolone The metabolism of Mobocertinib can be increased when combined with Triamcinolone. Triazolam The metabolism of Mobocertinib can be decreased when combined with Triazolam. Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Mobocertinib. Trimebutine The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Mobocertinib. Trimethadione The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Mobocertinib. Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Mobocertinib. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Mobocertinib. Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mobocertinib. Troglitazone The metabolism of Mobocertinib can be decreased when combined with Troglitazone. Troleandomycin The serum concentration of Mobocertinib can be increased when it is combined with Troleandomycin. Trovafloxacin The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Mobocertinib. Tucatinib The metabolism of Tucatinib can be decreased when combined with Mobocertinib. Udenafil The metabolism of Mobocertinib can be decreased when combined with Udenafil. Ulipristal The serum concentration of Ulipristal can be decreased when it is combined with Mobocertinib. Valbenazine The metabolism of Mobocertinib can be decreased when combined with Valbenazine. Valproic acid The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Mobocertinib. Vandetanib The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Mobocertinib. Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Mobocertinib. Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mobocertinib. Venetoclax The serum concentration of Venetoclax can be decreased when it is combined with Mobocertinib. Verapamil The metabolism of Mobocertinib can be decreased when combined with Verapamil. Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Mobocertinib. Vilanterol The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Mobocertinib. Viloxazine The metabolism of Mobocertinib can be decreased when combined with Viloxazine. Vinblastine The serum concentration of Vinblastine can be decreased when it is combined with Mobocertinib. Vincristine The serum concentration of Vincristine can be decreased when it is combined with Mobocertinib. Vindesine The serum concentration of Vindesine can be decreased when it is combined with Mobocertinib. Vinflunine The serum concentration of Vinflunine can be decreased when it is combined with Mobocertinib. Vinorelbine The serum concentration of Vinorelbine can be decreased when it is combined with Mobocertinib. Vonoprazan The metabolism of Mobocertinib can be decreased when combined with Vonoprazan. Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Mobocertinib. Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Mobocertinib. Vortioxetine The metabolism of Mobocertinib can be decreased when combined with Vortioxetine. Warfarin The serum concentration of Warfarin can be decreased when it is combined with Mobocertinib. Zaleplon The metabolism of Mobocertinib can be decreased when combined with Zaleplon. Zanubrutinib The serum concentration of Zanubrutinib can be decreased when it is combined with Mobocertinib. Zimelidine The metabolism of Mobocertinib can be decreased when combined with Zimelidine. Ziprasidone The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Mobocertinib. Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Mobocertinib. Zuclopenthixol The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Mobocertinib. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], EXKIVITY can cause fetal harm when administered to a pregnant woman. There are no available data on EXKIVITY use in pregnant women. Oral administration of mobocertinib to pregnant rats during the period of organogenesis resulted in embryolethality (embryo-fetal death) and maternal toxicity at plasma exposures approximately 1.7 times the human exposure based on AUC at the 160 mg once daily clinical dose (see Data). Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Lactation There are no data on the presence of mobocertinib or its metabolites in human milk or their effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with EXKIVITY and for 1 week after the last dose. How should this medicine be used?

Mobocertinib comes as a capsule to take by mouth. It is usually taken once daily with or without food. The length of your treatment depends on how well this medication works for you, and the side effects that you experience. Take mobocertinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take mobocertinib exactly as directed. Do not take more…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)